Umbilical Cord Blood Therapy Potentiated with Erythropoietin for Children with Cerebral Palsy: A Double-blind, Randomized, Placebo-Controlled Trial

• DOI: 10.1002/stem.1304
• Publication Date: 2012-12-24T05:39:02Z
• Authors: Kyunghoon Min; Junyoung Song; Jin Young Kang; Jooyeon Ko; Ju Seok Ryu; Myung Seo Kang; Su Jin Jang; Sang Heum Kim; Doyeun Oh; Moon Kyu Kim; Sung Soo Kim; MinYoung Kim
• Keywords: Male; Cerebral Palsy; Translational and Clinical Research; Infant; Fetal Blood; 3. Good health; Placebos; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Double-Blind Method; Fluorodeoxyglucose F18; Child, Preschool; Positron-Emission Tomography; Humans; Female; Radiopharmaceuticals; Child; Erythropoietin

Allogeneic umbilical cord blood (UCB) has therapeutic potential for cerebral palsy (CP). Concomitant administration of recombinant human erythropoietin (rhEPO) may boost the efficacy UCB, as it neurotrophic effects. The objectives this study were to assess safety and allogeneic UCB potentiated with rhEPO in children CP. Children CP randomly assigned one three parallel groups: pUCB group, which received rhEPO; EPO placebo UCB; Control rhEPO. All participants rehabilitation therapy. main outcomes changes scores on following measures during 6 months treatment period: gross motor performance measure (GMPM), function measure, Bayley scales infant development-II (BSID-II) Mental Motor (18). F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET/CT) diffusion tensor images (DTI) acquired at baseline followed up detect brain. In total, 96 subjects completed study. Compared (n = 33) 32) groups, 31) group had significantly higher GMPM BSID-II months. DTI revealed significant correlations between increment fractional anisotropy group. 18F-FDG-PET/CT showed differential activation deactivation patterns groups. incidence serious adverse events did not differ conclusion, ameliorated cognitive dysfunction undergoing active rehabilitation, accompanied by structural metabolic